{
  "docId": "019de076-9103-7399-8bed-9b1b1a8b182a",
  "docSlug": "93c36ca1f8977b3a70b566ce0ab54138",
  "documentTitle": "argenx SE | Investor Conference Presentation Deck | 27 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 27,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide highlights clinical outcomes (QoL, MG-ADL scores), treatment protocols (steroid tapering), patient support (My VYVGART Path), and economic value (cost/benefit vs IVIg).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9103-7399-8bed-9b1b1a8b182a/8",
  "deckHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a",
  "deckJsonHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a.json",
  "deckAnchorHref": "/decks/019de076-9103-7399-8bed-9b1b1a8b182a#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.74,
        "y": 0.17
      },
      "kind": "list",
      "text": "Superior cost/benefit over IVIg",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29f8a38f-fbec-4270-9f01-4581c15c1232",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.28,
        "y": 0.17
      },
      "kind": "list",
      "text": "Meaningful steroid tapering by at least 5mg/day within first 6 months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71f8efb3-3a74-4d4a-94d3-3baa2c26d0e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.05,
        "y": 0.17
      },
      "kind": "list",
      "text": "45% MSE QoL comparable to healthy population; 78% MG-ADL ≤4",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e541ed80-9b09-4a06-b7e6-635cfe193ca8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.51,
        "y": 0.17
      },
      "kind": "list",
      "text": "My VYVGART Path: Enables significantly faster access to treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc2d778a-4c4f-4426-9533-26ee7835ca91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.2,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "Estimated 4,000 patient years of safety follow-up between clinical trial and real-world experience",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a9ac852-a4cc-4ec2-a09b-e4d63afc0ce1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.02,
        "y": 0.8
      },
      "kind": "source-note",
      "text": "* Real world evidence **Source: ADAPT and ADAPT+ clinical trial data ***Leading Health Technology Assessment agency",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3daccf4-7410-4d73-8352-9c02363e6d06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "VYVGART is Setting New Expectations in gMG",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca6ad63f-a056-41f8-984a-a07d1f00e662",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "10300344-3ff1-4b97-95a5-8662d641a2aa",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Highlighting commercial execution and market opportunities",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 5,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "f381209b-40fa-4c32-8920-66d6dea883b8",
      "evidence": "Discussion of innovation horizons and market opportunities",
      "position": 0,
      "objective": "Why now is the time for argenx SE's innovation",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}